Search results
Results from the WOW.Com Content Network
Dora Nellie Richardson (1919-1998) was an organic chemist who first synthesised Tamoxifen in England in 1962. [1] She was born on 1 June 1919 and died in September 1998 in England. [2] Richardson decided to become a chemist after seeing people working in hospital laboratories while visiting her grandmother in hospital in London.
Tamoxifen, sold under the brand name Nolvadex among others, is a selective estrogen receptor modulator used to prevent breast cancer in women and men. [13] It is also being studied for other types of cancer. [13] It has been used for Albright syndrome. [14] Tamoxifen is typically taken daily by mouth for five years for breast cancer. [14]
AP Images; Bridgeman Art Library: California Digital Library: California State University, Northridge, Oviatt Library Digital Collections Camera Press: Chicago Daily News (1902–1933), collection of over 55,000 images on glass plate negatives Corbis Images: Depositphotos: Stock Images: 164,000,000+ (June 2020) Yes No Yes English (Default)+ 21 ...
Sivifene (A-007) was initially thought to be a SERM due to its structural similarity to tamoxifen but it was subsequently found not to bind to the estrogen receptor (ER). [8] Tesmilifene (DPPE; YMB-1002, BMS-217380-01) is also structurally related to tamoxifen but similarly does not bind to the ER and is not a SERM. [9] [10]
Jordan, V.C. A current view of tamoxifen for the treatment and prevention of breast cancer (Gaddum Memorial Lecture)" British Journal of Pharmacology 110:507-517, 1993. (257 citations as of May 26, 2021). Jordan, V.C. and Morrow, M.M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocrine Reviews 20:253-278, 1999.
N-Desmethyltamoxifen (developmental code name ICI-55,548) is a major metabolite of tamoxifen, a selective estrogen receptor modulator (SERM). [1] [2] N-Desmethyltamoxifen is further metabolized into endoxifen (4-hydroxy-N-desmethyltamoxifen), which is thought to be the major active form of tamoxifen in the body.
One of the largest breast cancer prevention studies ever, [2] it included 22,000 women in 400 medical centers in the United States and Canada. [3] [4] [5] The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen.
The most prevalent side effects for endoxifen include headache, vomiting, insomnia. Other side effects were: gastritis, epigastric discomfort, diarrhea, restlessness, somnolence, etc. [8] Some of the adverse events reported with other therapies for the management of manic episodes of bipolar I disorder were not observed during the clinical development program of endoxifen like reduction in ...